摘要
嗜酸细胞性肉芽肿性多血管炎(eosinophilia granulomatosis polyangiitis,EGPA)是一种临床少见但可累及全身多系统的自身免疫性疾病。当前诱导EGPA缓解和预防复发的药物主要是糖皮质激素和免疫抑制剂,患者在治疗过程中常出现复发和皮质类固醇依赖相关的问题,因此亟需新的治疗方法。奥马珠单抗(omalizumab,OMA)是一种人源化抗IgE单克隆抗体,在我国于2017年8月获批用于中重度变应性哮喘的治疗,已有超过3万例哮喘患者接受治疗,应用前景广阔。近年来OMA在EGPA中的应用研究日益增多,本文对近年来国内外使用OMA治疗EGPA的临床研究包括潜在药理机制、临床获益及不良反应等进行综述,为奥马珠单抗的相关临床治疗研究提供参考。
Eosinophilia granulomatosis polyangiitis(EGPA) is a rare clinical autoimmune disease that can involve multiple systems in the body. The current drugs for EGPA to induce remission and prevent relapse mainly include glucocorticoids and immunosuppressive agents. Patients often experience relapse and corticosteroid dependence-related problems during treatment, so new treatments are still urgently needed.Omalizumab(OMA) is a humanized anti-IgE monoclonal antibody that was approved in China in August 2017 for the treatment of moderate to severe allergic asthma. So far, more than 30 000 asthma patients have been treated with OMA, and its application is promising. In recent years, the application research of OMA in EGPA has also increased. This article reviews the clinical research on OMA treatment of EGPA at home and abroad in recent years, including the potential pharmacological mechanism, clinical benefits and adverse reactions, etc., for the reference of omalizumab-related clinical treatment research.
作者
马圆
崔博
陈智鸿
MA Yuan;CUI Bo;CHEN Zhi-hong(Department of Pulmonary and Critical Care Medicine,Zhongshan Hospital,Fudan University,Shanghai 200032,China)
出处
《复旦学报（医学版）》
CAS
CSCD
北大核心
2023年第1期134-139,共6页
Fudan University Journal of Medical Sciences
基金
国家自然科学基金(81970023,81470211)。
